Skip to main content

Advertisement

Table 1 Demographics, indications and outcomes

From: Prospective monitoring improves outcomes of primary total hip replacement: a cohort study

  Monitoring (n = 62) Control (n = 283) p-value
Age 68 (45–90) 62 (23–86) 0.68
Gender *    
   Female 45 (73) 206 (73) 0.94
   Male 17 (27) 77 (27)  
Indication *    
   OA 52 (84) 220 (78) 0.56
   RA 4 (6) 34 (12)  
   AVN 4 (6) 16 (6)  
   DDH 2 (3) 13 (5)  
Adverse Event *    
   Any AE 13 (21) 127 (45) <0.001
   Hip dislocation 0 (0) 17 (6) 0.05
   Oliguria 3 (5) 54 (19) 0.007
   SSI 0 (0) 8 (3) 0.37
   VTE 0 (0) 8 (3) 0.37
   ADR 8 (13) 31 (11) 0.66
VTEPP adherence * 61 (98) 241 (85) 0.002
  1. Abbreviations: OA: osteoarthritis; RA: rheumatoid arhtritis; AVN: avascular necrosis of the femoral head; DDH: developmental displasia of the hip; AE: adverse event; SSI: surgical site infection; VTE: venous thromboembolic event; ADR: adverse drug reaction; VTEPP: venous thromboembolic event prophylaxis protocol; † values as means in years, ranges in parentheses; * values as number of patients, percentages in parentheses.